Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Revenue (2023 - 2026)

Phathom Pharmaceuticals has reported Revenue over the past 4 years, most recently at $58.3 million for Q1 2026.

  • Quarterly Revenue rose 104.43% to $58.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $204.9 million through Mar 2026, up 150.3% year-over-year, with the annual reading at $175.1 million for FY2025, 216.93% up from the prior year.
  • Revenue was $58.3 million for Q1 2026 at Phathom Pharmaceuticals, up from $57.6 million in the prior quarter.
  • Over five years, Revenue peaked at $58.3 million in Q1 2026 and troughed at $682000.0 in Q4 2023.
  • The 4-year median for Revenue is $29.1 million (2024), against an average of $28.9 million.
  • Year-over-year, Revenue skyrocketed 4249.56% in 2024 and then soared 94.12% in 2025.
  • A 4-year view of Revenue shows it stood at $682000.0 in 2023, then skyrocketed by 4249.56% to $29.7 million in 2024, then surged by 94.12% to $57.6 million in 2025, then grew by 1.25% to $58.3 million in 2026.
  • Per Business Quant, the three most recent readings for PHAT's Revenue are $58.3 million (Q1 2026), $57.6 million (Q4 2025), and $49.5 million (Q3 2025).